Oculus spins off a new biotech; Adimab expands collaborations with Merck and Lilly;

Conversations on Twitter :

 @FierceBiotech: PATH, Inovio zero in on DNA malaria vaccine. News | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline commits venture $$$ to new $250M biotech startup fund--Sanderling 7, coming 9 years after the last one. Story | Follow @JohnCFierce

> Petaluma, CA-based Oculus Innovative Sciences ($OCLS) is spinning off its novel biotechnology business, Ruthigen. Oculus will retain all Microcyn drug and device indications while Ruthigen will focus on RUT58-60, a drug candidate designed to prevent infection in trauma and surgical procedures. Release

> Adimab has expanded its antibody development deals with Eli Lilly ($LLY) and Merck ($MRK). Story

> Life science exec David A. DeWahl, Jr., has taken the helm at Ischemix, which is developing a new drug designed to open narrowed arteries. Story

Medical Device News

 @FierceMedDev: GI Dynamics, Gore call off legal dogs in patent fight. Story | Follow @FierceMedDev

@MarkHFierce: A "smart socket" to connect to limb stump could lead to better prosthetic fit. U.K. scientists are doing all the work. Item | Follow @MarkHFierce

 @DamianFierce: At yesterday's FierceBiotech JPM13 panel, R&D experts debunked some Big Data myths and looked to a bright future. Editor's Corner | Follow @DamianFierce

> Ex-Orthofix manager gets home confinement in Medicare kickback case. Story

> This time, 'cautious optimism' at the J.P. Morgan Healthcare Conference. Editor's Corner

> Stryker: Hip device recalls could cost up to $390M. More

Pharma News

@FiercePharma: That pregnancy-drug/breast cancer liability suit? All wrapped. $LLY, 4 women reach deal on 2nd day of trial. More | Follow @FiercePharma

 @AlisonBFierce: A fast and early flu season here in the U.S. The CDC's weekly flu map looks grim. More | Follow @AlisonBFierce

> Lilly settles suit linking old miscarriage drug to breast cancer. News

> Eyeing Biogen drug, Teva demands review for new MS meds. Story

> FDA backs tech to throw off painkiller addicts. Article

> Don't expect GSK to spin off ViiV anytime soon, R&D chief says. Report

Vaccines News

> Widespread, early flu season grips United States. Item

> HPV-related cancers up despite vaccines from Merck, GSK. Story

> Altravax pulls in $1.2M from NIH. Article

> Pfizer wins Prevenar 13 expansion in EU. News

> India's vaccine prices soar as private companies gain ground. Story

Pharma Manufacturing News

> Hikma acquisition lands 2 plants in Egypt. Report

> Canada taps Tamiflu stash to help Roche meet demand. Article

> FDA inspectors come down hard on Taiwan plant. News

> More plant closings for Valeant. Story

And Finally… Want to survive your middle age? Investigators say a spouse or permanent companion may be key. Story



Suggested Articles

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.

The new parliamentary arithmetic gives Boris Johnson the numbers to pass the withdrawal agreement and take the U.K. out of the EU.